

PRESS RELEASE  
2 February 2010



## **Extraordinary General Meeting Approved Directed New Share Issue**

**Lund, 2 February 2010. Today's extraordinary general meeting in BioInvent International AB (publ) (OMXS: BINV) approved the Board of Director's decision to carry out a directed new share issue with deviation from the shareholders' preferential rights.**

The directed new share issue, which has been subscribed by DnB NOR Asset Management, the Nordic team for 1,521,800 shares and B & E Participation AB for 3,913,000 shares, raise approximately SEK 150 million before transaction expenses to the company. After the new share issue, B & E Participation AB will hold approximately 6.4 percent of the total number of shares in the company. In total, 5,434,800 shares will be issued and the subscription price is set to SEK 27.60 per share. The new issue results in an equity dilution of 8.9 percent and the subscription price represents a discount of 0.6 percent compared to the one month volume weighted average closing price.

First date of trade for the new shares is expected to be around 12 February 2010.

For further information, please refer to the press release made public on 14 January 2010 in relation to the Board of Director's decision.

-- END --

### **Notes to Editors:**

#### **About BioInvent**

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abelló, Bayer HealthCare, Daiichi Sankyo, ImmunoGen, Mitsubishi Tanabe, OrbusNeich, UCB and XOMA. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

### **For further information, please contact:**

#### ***BioInvent International AB***

Svein Mathisen  
President & CEO  
Tel: +46 (0)46-286 85 67  
Mobile: +46 (0)708-97 82 13  
E-mail: [svein.mathisen@bioinvent.com](mailto:svein.mathisen@bioinvent.com)

Cristina Glad  
Executive Vice President  
Tel: +46 (0)46-286 85 51  
Mobile: +46 (0)708-16 85 70  
E-mail: [cristina.glad@bioinvent.com](mailto:cristina.glad@bioinvent.com)

College Hill (media enquiries)  
Justine Lamond, Sue Charles, Benjamyn Tan  
Tel: +44 (0)20 7457 2020  
Erik Clausen, Kena Hudson (US)  
Tel: +1 415-230-5385  
E-mail: [bioinvent@collegehill.com](mailto:bioinvent@collegehill.com)

**BioInvent International AB (publ)**

Co. reg. No. 556537-7263,  
Address: Sölvegatan 41  
Mailing address: SE-223 70 LUND  
Tel: +46 (0)46 286 85 50  
[info@bioinvent.com](mailto:info@bioinvent.com)  
[www.bioinvent.com](http://www.bioinvent.com)

*BioInvent publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on 2 February 2010 at 5.00 p.m. CET.*

***Important information***

This announcement does not contain or constitute an offer to sell or the solicitation of an offer to buy securities in BioInvent International AB.